title: Biodegradable stents as a platform to drug loading.
abstract: Despite technical and mechanical improvement in coronary stents the incidence of restenosis caused by in-stent neointimal hyperplasia remains high. Oral administration of numerous pharmacological agents has failed to reduce restenosis after coronary stenting in humans, possibly owing to insufficient local drug concentration. Therefore, drug-eluting stents were developed as a vehicle for local drug administration. The authors developed a new drug-eluting polymer stent that is made of poly-l-lactic acid polymer mixed with tranilast, an anti-allergic drug that inhibits the migration and proliferation of vascular smooth muscle cells induced by platelet-derived growth factor and transforming growth factor->1. Polymer stents might be superior to polymer-coated metallic stents as local drug delivery stents in terms of biodegradation and the amount of loaded drug. Drug-mixed polymer stents can be loaded with a larger amount of drug than can drug-coated metallic stents because the polymer stent struts can contain the drug. Clinical application is required to assess the safety and efficacy of drug-eluting polymer stents against stent restenosis.
authors.affiliation: Department of Cardiology, Shiga Medical Center for Adults, Shiga, Japan. tamai@cct.gr.jp
authors.forename: Takafumi
authors.initials: T
authors.lastname: Tsuji
authors.forename: Hideo
authors.initials: H
authors.lastname: Tamai
authors.forename: Keiji
authors.initials: K
authors.lastname: Igaki
authors.forename: Eisho
authors.initials: E
authors.lastname: Kyo
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Kosuga
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Hata
authors.forename: Takuji
authors.initials: T
authors.lastname: Nakamura
authors.forename: Shinya
authors.initials: S
authors.lastname: Fujita
authors.forename: Shinsaku
authors.initials: S
authors.lastname: Takeda
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Motohara
authors.forename: Hiromu
authors.initials: H
authors.lastname: Uehata
mesh_terms: D020341:Absorbable Implants; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011091:Polyesters; D015607:Stents; D013552:Swine; D062367:ortho-Aminobenzoates / Q000008:administration & dosage*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010975:Platelet Aggregation Inhibitors; D011091:Polyesters; D062367:ortho-Aminobenzoates; C033616:poly(lactide); C012293:tranilast